Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
R.B. Caro
Observed name:
R. Caro
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario Virgen del Rocío,
GEICAM – Spanish Breast Cancer Group,
Vall d'Hebron Institute of Oncology
ORCID:
0000-0001-8377-747X
Observed ORCID:
0000-0001-8377-747X
OpenAlex ID:
A5023192333
OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
2023
·
S.V. Liu
, R. Dziadziuszko
, et al.
·
Journal of Thoracic Oncology
·
45
PDF
P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
2021
·
N. Patil
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
18
A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)
2016
·
M. Martín
, M. Ruiz-Borrego
, et al.
·
Annals of Oncology
·
3
PDF
OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
2021
·
S.S. Ramalingam
, T.E. Ciuleanu
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
2021
·
D.R. Spigel
, L.G. Paz-Ares
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
2021
·
L. Paz-Ares
, D.R. Spigel
, et al.
·
Journal of Thoracic Oncology
·
1
OA09.02 I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC
2025
·
A. Prelaj
, V. Mišković
, et al.
·
Journal of Thoracic Oncology
1935P Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment
2025
·
I. Priano
, R. Caro
, et al.
·
Annals of Oncology
PDF
2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
2023
·
S.M. Cedres Perez
, A.A. Valdivia
, et al.
·
Annals of Oncology
PDF
P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
2021
·
L. Paz-Ares
, D.R. Spigel
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
10
Citation count:
71
H-index:
3
I10-index:
2
Year
Topic
Type